Deepinder Goyal's new wearable startup Temple acquired London-based longevity science firm Longevous, immediately bringing its two Oxford-trained founders onboard. The move means Temple's pre-launch scientific validation now includes a Chief Medical Officer and a Head of Science, both of whom already pressure-tested its core "Entropy" technology. This fast-tracks Temple's claim to "evidence-based longevity" by integrating external scientific rigor at an early stage.
How We Got Here
Temple was founded by Goyal in 2024, focusing on wearable technology for health tracking and longevity. The startup has been building an in-house science team, with this acquisition adding external clinical and research capabilities ahead of its planned launch.
The Numbers
- Longevous founders Dr. Robert Mohr and Dr. Avi Roy will join Temple full-time.
- Dr. Robert Mohr, with nearly two decades of clinical experience, is now Temple's Chief Medical Officer.
- Dr. Avi Roy, an Oxford-trained biomedical scientist, is now Temple's Head of Science.
- Mohr and Roy tested Temple's Entropy technology and data for two months before the acquisition.
- Longevous will continue to operate as part of Temple, with Mohr and Roy personally looking after existing clients.
What Happens Next
🇮🇳 Why This Matters for India
For Bangalore's deep-tech founders building in health and wellness, this shows how quickly top scientific talent can be imported for specialized, early-stage product validation.
The Take
This acquisition signals Goyal understands the sheer difficulty of building genuine scientific credibility in the longevity space from scratch. Temple now skips years of organic team building, positioning itself to launch with an immediate, evidence-based moat against new entrants.
Source:
YourStory ↗